MoonLake Immunotherapeutics (MLTX) risk factors, FY2025 10-K

Risks Related to Our Limited Operating History, Business, Financial Condition, and Results of Operations

1. 01We have a limited operating history and have no products approved for commercial sale
2. 02We have incurred losses since inception, and we expect to incur significant losses for the foreseeable future and may not be able to achieve or sustain profitability in the future. We have not generated any revenue from SLK and may never generate revenue or become profitable
3. 03If we are unable to raise capital when needed, or on acceptable terms, we may be forced to delay, reduce and/or eliminate one or more of our development programs or future commercialization efforts, which would have a negative impact on our business, prospects, operating results and financial condition
4. 04Our business relies on certain licensing rights from MHKDG and RCT that can be terminated in certain circumstances. If we breach those agreements, or if we are unable to satisfy our diligence obligations under which we license rights to SLK from MHKDG, we could lose the ability to develop and commercialize SLK52% rewritten
5. 05import and otherwise commercialize SLK on a world-wide basis, subject to certain restrictions. This agreement replaces our sublicense for similar rights under the License Agreement with MHKDGNew
6. 06We may be required to take write-downs or write-offs, restructuring and impairment or other charges that could have a significant negative effect on our financial condition, results of operations and stock price, which could cause you to lose some or all of your investment71% rewritten
7. 07If the market opportunities for our approved product candidates, if any, are smaller than we expect, it could materially and adversely affect our financial condition and results of operation
8. 08Even if SLK or other compounds we may develop are successful in clinical trials and receive regulatory approvals, we or our collaboration partners may not be able to successfully commercialize them
9. 09The Loan and Security Agreement contains certain covenants that could adversely affect our operations and, if an event of default were to occur, we could be forced to repay any outstanding indebtedness sooner than planned and possibly at a time when we do not have sufficient capital to meet this obligationNew

Risks Related to Product Development

1. 10We have never successfully completed the regulatory approval process for any of our product candidates and we may be unable to do so for any product candidates we acquire or develop
2. 11We are substantially dependent on the success of SLK, and our ongoing and anticipated clinical trials of SLK may not be successful93% rewritten
3. 12results from our S-OLARIS clinical trial in February 2026 and are currently evaluating the next steps to complete the clinical development of SLK in this indicationNew
4. 13We may find it difficult to enroll patients in our clinical trials. If we experience delays or difficulties in the enrollment of patients in clinical trials, our successful completion of clinical trials or receipt of marketing approvals could be delayed or prevented
5. 14The results of preclinical testing and early clinical trials may not be predictive of the success of our later clinical trials, and the results of our clinical trials may not satisfy the requirements of the FDA, EMA, or other comparable foreign regulatory authorities
6. 15Preclinical and clinical development involves a lengthy and expensive process with uncertain outcomes, and results of earlier studies and trials may not be predictive of future clinical trial results37% rewritten
7. 16Preliminary, interim data from our clinical trials that we announce or publish may change as more patient data become available and are subject to audit and verification procedures
8. 17We face substantial competition, which may result in others discovering, developing, licensing or commercializing products before or more successfully than we do34% rewritten
9. 18SLK may have a safety profile that could prevent regulatory approval, marketing approval or market acceptance, or limit its commercial potential
10. 19Geopolitical events and global economic conditions, such as public health crises, the conflicts between Russia and Ukraine and in the Middle East, could seriously and adversely affect our preclinical studies and ongoing and anticipated clinical trials, business, financial condition and results of operations44% rewritten
11. 20sickness of employees or their families, the desire of employees to avoid travel or contact with large groups of people, an increased reliance on working from home, school closures or mass transit disruptionsNew

Risks Related to Regulatory Process and Other Legal Compliance Matters

1. 21clinical trial results may result in our failing to obtain regulatory approval to market SLK, which would significantly harm our business, results of operations and prospectsNew
2. 22We will be subject to extensive ongoing regulatory obligations and continued regulatory review, which may result in significant additional expense and we may be subject to penalties if we fail to comply with regulatory requirements or experience unanticipated problems with SLK47% rewritten
3. 23Due to unfavorable pricing regulations and/or third-party coverage and reimbursement policies, we may not be able to offer SLK at competitive prices which would seriously harm our business
4. 24Failure to comply with the laws and regulations prohibiting the promotion of off-label uses can result in, among other things, adverse publicity, warning letters, corrective advertising and potential civil and criminal penalties
5. 25Our employees, independent contractors, consultants, commercial collaborators, principal investigators, CROs, suppliers and vendors may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements64% rewritten
6. 26Our business operations and current and future arrangements with investigators, healthcare professionals, consultants, third-party payors, patient organizations and customers will be subject to applicable healthcare regulatory laws, which could expose us to penaltiesNew
7. 27The healthcare system is under significant financial pressure to reduce costs, which could reduce payment and reimbursement rates for drugs
8. 28Pharmaceutical and biological product marketing is subject to substantial regulation in the United States and EU, and any failure by us or our future commercial and collaborative partners to comply with applicable statutes or regulations can adversely affect our businessNew
9. 29If we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could have a material adverse effect on the success of our business
10. 30We are subject to laws and regulations related to privacy, data protection, information security and consumer protection across different markets where we conduct our business. Our actual or perceived failure to comply with such obligations could harm our business30% rewritten
11. 31engaging processors. Breaches of or non-compliance with applicable data protection regulations and professional secrecy obligations could result in fines, or, under certain circumstances, criminal sanctionsNew
12. 32The Cayman Islands Economic Substance Act may affect our operations
13. 33Current and future legislation may increase the difficulty and cost for us, and any collaborators, to obtain marketing approval of and commercialize our drug candidates and affect the prices we, or they, may obtain
14. 34We may be subject to adverse legislative or regulatory tax changes that could negatively impact our financial conditionNew

Risks Related to Employee Matters, Managing Our Growth and Other Risks Related to Our Business

1. 35We are dependent on our key personnel and anticipate hiring new key personnel. If we are not successful in attracting and retaining qualified personnel, we may not be able to successfully implement our business strategy
2. 36In order to successfully implement our plans and strategies, we will need to grow the size of our organization and we may experience difficulties in managing this growth
3. 37A cybersecurity incident or failure in our information technology and storage systems or those of third parties upon whom we rely could significantly disrupt the operation of our business and adversely impact our financial condition
4. 38Furthermore, parties in our supply chain may be operating from single sites, increasing their vulnerability to natural disasters or other sudden, unforeseen, and severe adverse events. If such an event were to affect our supply chain, it could have a material adverse effect on our business95% rewritten

Risks Related to Reliance on Third Parties

1. 39We currently rely on third parties to produce and process SLK. Our business could be adversely affected if the third-party manufacturers fail to provide us with sufficient quantities of SLK or fail to do so at acceptable quality levels or prices
2. 40We do not currently own or operate any facility that may be used to produce SLK (including any drug substance or finished drug product) and must currently rely on CMOs to produce them for us. We have not yet caused SLK to be manufactured in a commercially validated and registered process and may not be able to do so
3. 41We may, in the future, form or seek collaborations or strategic alliances or enter into licensing arrangements, and we may not realize the benefits of such collaborations, alliances or licensing arrangementsNew

Risks Related to Our Intellectual Property

1. 42Our ability to protect our patents and other proprietary rights is uncertain, exposing us to the possible loss of competitive advantage
2. 43We enjoy only limited geographical protection with respect to certain patents and may not be able to protect our intellectual property rights throughout the world
3. 44Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated if we fail to comply with these requirements
4. 45Issued patents covering one or more of our drug candidates could be found invalid or unenforceable
5. 46We may be subject to damages resulting from claims that we or our employees have wrongfully used or disclosed confidential information of our competitors or are in breach of non-competition or non-solicitation agreements with our competitors
6. 47Patent terms may be inadequate to protect our competitive position with respect to SLK for an adequate amount of time
7. 48If we do not obtain patent term extension in the United States under the Hatch-Waxman Act and in foreign countries under similar legislation, thereby potentially extending the term of our marketing exclusivity for SLK, our business may be materially harmed
8. 49Changes to patent laws in the United States and other jurisdictions could diminish the value of patents in general, thereby impairing our ability to protect SLK43% rewritten
9. 50We may not identify relevant third-party patents or may incorrectly interpret the relevance, scope or expiration of a third-party patent, which might adversely affect our ability to develop and market SLKNew
10. 51We may be subject to claims challenging the inventorship of our patents and other intellectual property
11. 52We may be subject to patent infringement claims or may need to file claims to protect our intellectual property, which could result in substantial costs and liability and prevent us from commercializing SLK32% rewritten
12. 53claim, a third-party could potentially provide evidence in a USPTO proceeding sufficient for the USPTO to hold a claim invalid even though the same evidence would be insufficient to invalidate the claim if first presented in a district court actionNew
13. 54We license patent rights from third-party owners and thus our rights to develop and commercialize our technology and product candidates are subject, in part, to the terms and conditions of licenses granted to us by others23% rewritten
14. 55Our license from MHKDG may be subject to retained rightsNew
15. 56We may not be able to effectively secure first-tier technologies when competing against other companies or investors
16. 57Numerous factors may limit any potential competitive advantage provided by our intellectual property rights
17. 58If approved, our product candidates that are regulated as biologics may face competition from biosimilars approved through an abbreviated regulatory pathway

Risks Related to Our Class A Ordinary Shares

1. 59The price of our shares has been, and may continue to be volatile, and you could lose all or part of your investment25% rewritten
2. 60If our share price is volatile, we may be subject to securities litigation, which is expensive and could divert management attention58% rewritten
3. 61Sales of our Class A Ordinary Shares, or the perception that such sales may occur, may cause the market price of the Class A Ordinary Shares to decline significantly, even if our business is doing well
4. 62Our principal shareholders and management own a significant percentage of our stock and are able to exert significant influence over matters subject to shareholder approval
5. 63Anti-takeover provisions in our organizational documents could delay or prevent a change of control55% rewritten
6. 64Our indemnification obligations to our officers and directors may result in a significant cost to us and hurt the interests of our shareholdersNew
7. 65expenses as incurred, to the fullest extent permitted under applicable law, from damage arising from the fact that such person is or was an officer or director of our Company or its subsidiariesNew
8. 66Because we do not anticipate paying any cash dividends on our capital stock in the foreseeable future, capital appreciation, if any, will be your sole source of gain
9. 67Future issuances of debt securities and equity securities may adversely affect our Company, including the market price of our Class A Ordinary Shares and may be dilutive to existing shareholders
10. 68We may become a foreign private issuer within the meaning of the rules under the Exchange Act, and as such we would be exempt from certain provisions applicable to U.S. domestic public companies
11. 69Accordingly, the information we would be required to file with or furnish to the SEC as a foreign private issuer is less extensive and less frequent as compared to the information required to be filed with the SEC by U.S. domestic issuers